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Abstract Although the association between in utero
exposure to diethylstilbestrol (DES) and clear cell adeno-
carcinoma of the cervix and vagina (CCA) was ﬁrst reported
among young women, subsequent case reports and cohort
studiessuggestthatanelevatedriskforCCAmaypersistwith
age. Data from the National Program of Cancer Registries
(NPCR)andtheSurveillance,EpidemiologyandEndResults
(SEER)Programwereusedtoconstructindirectstandardized
incidence ratios (SIR) comparing CCA risk among women
born during the exposure period 1947 through 1971, when
DES was prescribed to pregnant women, to the relevant time
period for nonexposed women born before or after DES
exposure period. CCA incidence among the women born
before the DES exposure period (ages 30–54 at diagnosis of
CAA) or after the DES exposure period (ages 15–29 at
diagnosis) were used to calculate the expected rates for
women born during the DES exposure period. Among
women aged 15–29 years, CCA risk increased with age and
peaked in the 25–29 year age group, but the risk estimates
were unstable (SIR = 6.06; 95% CI: 0.97, -251.07, SEER
data). Among women aged 40–54 years, CCA risk was
greatest in the 40–44 year age group (SIR = 4.55; 95% CI:
1.11, 40.19, SEER data and SIR = 3.94; 95% CI: 1.06,
33.01, NPCR/SEER data) and remained signiﬁcantly ele-
vated throughout this age group in the combined data set.
Risk was not elevated among women aged 30–39 years. The
observed risk of CCA, if causally related to DES exposure,
reﬂectsa persistenthealthimpactfrominuteroexposurethat
is widespread in the general population. When assessing a
woman’s cancer risks, whether her mother took DES while
pregnant may still be a relevant aspect of the medical history
for women born during the period of DES use in pregnancy.
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Introduction
The association between clear cell adenocarcinoma of the
vagina and cervix (CCA) and in utero exposure to diethyl-
stilbestrol (DES) was ﬁrst described in a case series in 1971
[1]. Since then, the strong and causal association between in
utero DES exposure and CCA has been ﬁrmly established
through the follow-up of several DES exposed cohorts, both
in the United States and the Netherlands [2, 3]. Early anal-
yses described an excess of CCA that peaked during late
adolescence and early adulthood [2, 3], but individual case
reports ofCCAandfollow-up ofestablished cohorts suggest
an elevation in risk persisting as the cohort aged [4, 5]. The
established cohorts of exposed women, however, represent
only a small fraction of the women who were exposed to
DES. Approximately 2–4 million mothers and their off-
spring in the United States, and perhaps more, may have
been exposed to DES during the period when DES was
prescribed for pregnant women [6, 7].
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based central cancer registries that participate in the
Centers for Disease Control and Prevention (CDC)’s
National Program of Cancer Registries (NPCR) and/or the
National Cancer Institute (NCI)’s Surveillance, Epidemiol-
ogy, and End Results (SEER) Program provides a unique
opportunity toexamine the potential population impact ofin
utero DES exposure. Using data from these programs, we
conducted an analysis comparing CCA risk among women
born during the time period when prenatal exposure to DES
wasmostcommonwithriskofCCAamongwomenbornina
period when DES was not in use.
Materials and methods
Incidence and population data
Cancer incidence data comes from the two federal cancer
surveillance programs: the NCI’s SEER Program, and the
CDC’s NPCR [8, 9]. Brieﬂy, the SEER Program began in
1973 with 5 state cancer registries and 4 others covering
10% of the US population (SEER-9). The NPCR began in
the mid-1990s with support to cancer registries in the
remaining 45 states and the District of Columbia. Together,
NPCR and SEER cover 100% of the US population. Patient
demographic and cancer related data are collected and
reported to CDC and NCI according to standards estab-
lished by the North American Association of Central
Cancer Registries (NAACCR) [10].
We examined invasive clear cell adenoma carcinomas
of the cervix or vagina (CCA) using ICD-O-3 morphology
code 8310/3 and site codes C52 and C53, respectively [11].
Cancer incidence data meeting high quality standards [10]
for women aged 15–54 years at diagnosis were extracted
from both the SEER and the NPCR databases. Information
for women diagnosed from 1973 through 2007 was avail-
able from the SEER-9 database [12], and for women
diagnosed from 1998 through 2006 from the combined
SEER/NPCR database (38 cancer registries, covering 63%
of the US population) [9]. County level population esti-
mates were produced by the US Census Bureau with fur-
ther reﬁnements by NCI [13].
Analyses
The years between 1947 through 1971 were selected as
representative of the period during which pregnant women
were most frequently prescribed DES in the United States
[6]. Figure 1 illustrates the progression of this cohort of
women by age and calendar year and the age groups cov-
ered by each registry data source. In 1973, when the SEER
Program began, these women were between the ages of 2
and 26 years. In calendar year 2007, the latest year for
which SEER data were available, these women were
between the ages of 36 and 60 years. In 1998, the ﬁrst year
that combined SEER/NPCR data were available, these
women were between the ages of 27 and 51 years. In 2006,
the latest year for which combined data were available,
these women were between the ages of 35 and 59 years.
Standardized incidence ratio (SIR)s were calculated as
follows [14]. SEER-9 data were used to estimate incidence
rates among comparison women born prior to 1947 or after
1971 in each 5-year age group (Table 1). The associated
incidence rates of CCA in these comparison groups were
then multiplied by the age-speciﬁc estimates of the popu-
lation at risk in the target birth cohort in the SEER-9 and
combined NPCR/SEER datasets to calculate an expected
case count. SEER*Stat [15] was used to estimate the age-
speciﬁc incidence rates. An observed to expected (O/E)
ratio was calculated for each 5 year age group. The cor-
responding 95% conﬁdence intervals were calculated based
on exact intervals for the binomial probability of occur-
rence during the exposure period.
Results
Among women born between 1947 and 1971, more cases
of CCA were observed than expected among women aged
15–29 years (Table 2). Counts increased with age, but risk
estimates were unstable with wide conﬁdence intervals.
More cases of CCA also were observed among women
aged 40–54 years; the SIR estimate was signiﬁcantly ele-
vated for the 40–44 year age group in both the SEER-9
data set (SIR = 4.55; 95% CI:1.11, 40.19) and NPCR/
SEER data set (SIR = 3.94; 95% CI: 1.06, 33.01), and
signiﬁcantly elevated throughout the 40–54 year age group
in the combined data set. Risk was not elevated among
women aged 30–39 years.
Discussion
This study measured an increase in the incidence of CCA
among young women in their late teens and 20s who were
born in the United States during the period when DES was
prescribed to pregnant women, consistent with the lag
period following in utero exposure that had been described
in previous reports [1–3]. Although we did not observe
elevated risks for women in their 30s, a second peak in risk
was observed among women after age 40. Our results are
consistent with the experience of the DES exposed cohort
in the Netherlands which also demonstrated an elevated
risk of CCA after age 40 [5]. In the follow-up of the NCI
combined cohort of DES exposed women through 2001,
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123the oldest case occurred at age 39 [4]. A bimodal age
distribution in CCA had been observed among women in
the Netherlands who had not been exposed in utero to DES,
leading the authors to suggest that menarche and meno-
pause might promote the development of CCA [2].
It has been estimated that between 1 and 2 million
mothers the United States used DES while pregnant
between 1947 and 1971, representing an exposure preva-
lence of about 1–2% [6]. If the observed increase in risk for
CCA was due primarily to DES exposure, then the mag-
nitude of the risk among DES exposed women was sub-
stantially underestimated due to the dilution effect of
combining exposed and unexposed women in one group.
Studies of cohorts with documented exposure to DES have
reported SIRs for CCA of 24 [5] and close to 40 [4]. In
addition, we were unable to adjust for temporal variation in
prenatal use of DES over time. Although prenatal use of
DES occurred primarily between 1947 and 1971, some use
occurred starting as early as 1940 and a small number of
the women who were born in the early 1940s and assumed
to be ‘‘unexposed’’ (Table 1) might have been exposed.
The resulting bias could have led to an underestimate of the
risk among women in their 30s. The probability that a
woman was exposed prenatally to DES was greatest for
women born in the early 1950s when the prevalence of use
peaked [6]. However, the lack of SEER cancer incidence
data before 1972 and the lack of NPCR/SEER data before
1998 limited the range of birth years that could be exam-
ined (Table 2). This could have attenuated the measure of
risk, especially at the youngest ages. Some analyses used
data from SEER registries in nine geographic areas:
Atlanta, Connecticut, Detroit, Hawaii, Iowa, New Mexico,
San Francisco-Oakland, Seattle-Puget Sound, and Utah.
Differences in risk estimates based on SEER data com-
pared to the combined NPCR/SEER data, which includes
many more areas, could be inﬂuenced by geographic dif-
ferences in the prevalence of DES use.
Other than older age, DES is the most studied risk factor
for CCA. Even among women with known in utero expo-
sure to DES, however, the incidence rate of CCA is very
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Fig. 1 Birth cohorts of women
born before, during and after the
period of DES use during
pregnancy, by age and calendar
year
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123low. The availability of high quality cancer incidence data
with large nationwide coverage in the NPCR/SEER data-
base enabled the examination of the occurrence of a very
rare cancer using indirect standardization of rates. When
age-speciﬁc risk estimates could be obtained using both
SEER data and the combined NPCR/SEER data, the larger
numbers available from the combined data set resulted in
more stable estimates. The methods employed for this
analysis could be repeated at periodic intervals in the future
to examine CCA risk as women age. These methods also
may have application for the examination of temporal
trends or birth cohort patterns for other rare cancers.
These data suggest that the cohort of US women born
during the period of DES use by pregnant women experi-
enced an increased risk for CCA that continued for dec-
ades, longer than had been projected previously [16]. If the
marked elevated risk of CCA among this birth cohort was
due primarily to in utero DES exposure, our ﬁndings sug-
gest that the large number of women exposed in utero to
DES in the United States may still be at special risk for
CCA as they grow older. The American Congress of
Obstetricians and Gynecologists advises that women
exposed to DES in utero may need more frequent cervical
cytology screening than that recommended for other
women [17]. The National Cancer Institute advises that
such exposed women also be given a ‘‘four-quadrant’’ Pap
test, in which cell samples are taken from all sides of the
upper vagina [18]. The American Cancer Society also
speciﬁes some differences in cervical screening recom-
mendations for women with in utero exposure to DES [19].
Women exposed to DES in utero also have been shown to
be at elevated risk of breast cancer [20]. To adequately
assess a woman’s risks for developing cancer and to inform
screening decisions for breast and cervical cancer,
Table 1 Diagnosis years and age-speciﬁc annual incidence rates of
clear cell adenocarcinoma of the cervix and vagina in the standard
population of unexposed women (women born before 1947 or after
1971)
Age at diagnosis
(years)
Year
of birth
Diagnosis
years
CCA rate per
million among the
unexposed cohort
50–54 1919–1946 1973–1996 0.585
45–49 1924–1946 1973–1991 0.275
40–44 1929–1946 1973–1986 0.244
35–39 1934–1946 1973–1981 0.549
30–34 1939–1946 1973–1976 0.385
25–29 1972–1982 2001–2007 0.157
20–24 1972–1987 1996–2007 0.376
15–19 1972–1992 1991–2007 0.267
Source:Surveillance,Epidemiology,andEndResults(SEER)Program
(www.seer.cancer.gov) SEER*Stat Database: Incidence—SEER 17
Regs Research Data ? Hurricane Katrina Impacted Louisiana Cases,
Nov 2009 Sub (1973–2007 varying), Surveillance Research Program,
Cancer Statistics Branch, released April 2010, based on the November
2009 submission
Table 2 Observed (O) and expected (E) case counts and observed to expected (O/E) incidence ratio of clear cell adenocarcinoma of the cervix
and vagina and year of diagnosis among women born between 1947 and 1971 by age at diagnosis
Age at diagnosis
(years)
Year of birth Diagnosis
year
Woman-years
at risk
Count O/E (95% CI)
EO
SEER-9
50–54 1947–1957 2001–2007 6,804,953 3.98 7 1.76 (0.54, 5.55)
45–49 1947–1962 1996–2007 12,340,335 3.40 6 1.77 (0.38, 10.91)
40–44 1947–1967 1991–2007 17,976,258 4.39 20 4.55 (1.11, 40.19)
35–39 1947–1971 1986–2006 22,012,143 12.09 17 1.41 (0.41, 7.49)
30–34 1947–1971 1981–2001 21,875,328 8.43 8 0.95 (0.13, 42.13)
25–29 1947–1971 1976–1996 20,996,957 3.30 20 6.06 (0.97, 51.07)
20–24 1949–1971 1973–1991 17,762,944 6.67 20 3.00 (1.00, 12.06)
15–19 1954–1971 1973–1986 12,793,442 3.42 8 2.34 (0.63, 10.62)
NPCR/SEER data
50–54 1947–1956 2001–2006 59,320,387 34.71 77 2.22 (1.07, 5.32)
45–49 1949–1961 1998–2006 95,727,032 26.35 93 3.53 (1.17, 17.42)
40–44 1954–1966 1998–2006 101,761,290 24.86 98 3.94 (1.06, 33.01)
35–39 1959–1971 1998–2006 97,726,456 53.69 53 0.99 (0.32, 4.94)
30–34 1964–1971 1998–2001 40,515,385 15.61 13 0.83 (0.13, 35.40)
Source: Data are from population-based cancer registries that participate in the National Program of Cancer Registries (NPCR) and/or the
Surveillance, Epidemiology, and End Results (SEER) Program and meet high quality data criteria. These registries cover 79.5% of the population
for 1999–2006
210 Cancer Causes Control (2012) 23:207–211
123information on possible prenatal exposure to DES, if
available, may be a relevant factor to consider for women
born when DES was prescribed to pregnant women.
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